Wright Gavin J, Rayner Julian C
Cell Surface Signalling Laboratory, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom; Malaria Programme, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom.
Malaria Programme, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom.
PLoS Pathog. 2014 Mar 20;10(3):e1003943. doi: 10.1371/journal.ppat.1003943. eCollection 2014 Mar.
All the symptoms and pathology of malaria are caused by the intraerythrocytic stages of the Plasmodium parasite life cycle. Because Plasmodium parasites cannot replicate outside a host cell, their ability to recognize and invade erythrocytes is an essential step for both parasite survival and malaria pathogenesis. This makes invasion a conceptually attractive vaccine target, especially because it is one of the few stages when the parasite is directly exposed to the host humoral immune system. This apparent vulnerability, however, has been countered by the parasite, which has evolved sophisticated molecular mechanisms to evade the host immune response so that parasites asymptomatically replicate within immune individuals. These mechanisms include the expansion of parasite invasion ligands, resulting in multiple and apparently redundant invasion "pathways", highly polymorphic parasite surface proteins that are immunologically distinct, and parasite proteins which are poorly immunogenic. These formidable defences have so far thwarted attempts to develop an effective blood-stage vaccine, leading many to question whether there really is an exploitable chink in the parasite's immune evasion defences. Here, we review recent advances in the molecular understanding of the P. falciparum erythrocyte invasion field, discuss some of the challenges that have so far prevented the development of blood-stage vaccines, and conclude that the parasite invasion ligand RH5 represents an essential pinch point that might be vulnerable to vaccination.
疟疾的所有症状和病理变化都是由疟原虫生命周期中的红细胞内阶段引起的。由于疟原虫无法在宿主细胞外复制,它们识别和侵入红细胞的能力对于寄生虫的生存和疟疾的发病机制而言都是至关重要的一步。这使得侵入成为一个在概念上颇具吸引力的疫苗靶点,特别是因为这是寄生虫直接暴露于宿主体液免疫系统的少数阶段之一。然而,寄生虫已经进化出复杂的分子机制来逃避宿主免疫反应,从而在免疫个体内无症状地复制,这抵消了这种明显的易损性。这些机制包括寄生虫侵入配体的扩增,导致多种且明显冗余的侵入“途径”、免疫上不同的高度多态性寄生虫表面蛋白,以及免疫原性较差的寄生虫蛋白。迄今为止,这些强大的防御措施挫败了开发有效的血液阶段疫苗的尝试,导致许多人质疑寄生虫的免疫逃避防御中是否真的存在可利用的漏洞。在此,我们综述了对恶性疟原虫红细胞侵入领域分子理解的最新进展,讨论了迄今为止阻碍血液阶段疫苗开发的一些挑战,并得出结论,寄生虫侵入配体RH5代表了一个可能易受疫苗接种影响的关键薄弱点。